.

follow-on-google-news

The Indian stock market remained open last week on Saturday, that is, 18th May, and conducted a special live trading session to test its ability to withstand unexpected events, while, due to the Mumbai parliamentary elections on Monday, the stock market remain closed. 

Even though the markets were closed, the listed companies have reported financial results for Q4 FY23-24 and FY24, through the regulatory filings with the stock exchanges, and the fluctuations in the share prices will be observed on Tuesday. 

Here are a few stocks to watch out for tomorrow that have reported financial results for Q4 FY23-24 and FY24 during closed market hours. 

Note: If you want to learn Candlesticks and Chart Trading from Scratch, here’s the best book available on Amazon! Get the book now!

Shankara Building Products Limited 

Shankara Building Products Ltd. is one of the leading organised retailers of home improvement and building products in India, operating under the brand name Shankara BuildPro. 

With a market capitalisation of Rs. 1,617.31 crore, the share price of this stock jumped by 3 percent to hit an intraday high at Rs. 670.15 in the trading session Saturday, compared to its previous closing price of Rs. 650.7. 

The consolidated revenue from operations increased by 13.8 percent YoY from Rs. 1,210 crore in Q4 FY22-23 to Rs. 1,376.55 crore in Q4 FY23-24, as well as by 17 percent QoQ from Rs. 1,177.3 crore in Q3 FY23-24 to Rs. 1,376.55 crore in Q4 FY23-24. 

The net profit of Shankara Building Products stood at Rs. 24.22 crore in Q4 FY23-24, rising by 26.5 percent YoY from Rs. 19.14 crore in Q4 FY22-23, and by 13.1 percent QoQ from Rs. 21.42 crore in Q3 FY23-24. 

Thangamayil Jewellery Limited 

Thangamayil Jewellery Ltd. is one of the leading jewellery retailers in Madurai, Tamil Nadu, and trades in Gold Jewellery, Diamond and Platinum jewels. 

The company reported a 21.4 percent YoY growth in income from operations from Rs. 3,156 crore in FY22-23 to Rs. 3,832.2 crore in FY23-24, as well as a rise of 9.7 percent QoQ from Rs. 896 crore in Q3 FY23-24 to Rs. 982.74 crore in Q4 FY23-24.

The net profit stood at Rs. 28.24 crore in Q4 FY23-24, rising by 0.85 percent QoQ from Rs. 28 crore in Q3 FY23-24, and by 54.55 percent YoY from Rs. 79.74 crore in FY22-23 to Rs. 123.24 crore in FY23-24 . 

With a market capitalisation of Rs. 3,429.21 crore, the share price of this small-cap stock jumped by nearly 1 percent to hit an intraday high at Rs. 1,257.3 in the trading session Saturday, compared to its previous closing price of Rs. 1,246.05. 

Windlas Biotech Limited 

Incorporated in 2001, Windlas Biotech Ltd. provides pharmaceutical development services, large-scale manufacturing services and affordable products to its customers and consumers worldwide. 

With a market capitalisation of Rs. 1,199.45 crore, the share price of this pharma stock jumped by 3.35 percent to hit an intraday high at Rs. 560.95 in the trading session Saturday, compared to its previous closing price of Rs. 542.8. 

The consolidated revenue from operations increased by 22 percent YoY from Rs. 141 crore in Q4 FY22-23 to Rs. 171.3 crore in Q4 FY23-24, as well as by 5.6 percent QoQ from Rs. 162.21 crore in Q3 FY23-24 to Rs. 171.3 crore in Q4 FY23-24. 

The net profit of Windlas Biotech stood at Rs. 17 crore in Q4 FY23-24, rising by 49.12 percent YoY from Rs. 11.4 crore in Q4 FY22-23, and by 13.3 percent QoQ from Rs. 15 crore in Q3 FY23-24. 

The earnings per share (EPS) experienced a growth i.e. in FY23-24 the EPS stood at Rs. 27.97, indicating a growth of 42 percent YoY and in Q4 FY23-24, the EPS stood at Rs. 8.17 YoY, representing a growth of 52 percent. 

Written by Shivani Singh

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.